Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors

Inclusion criteria

* Histologically confirmed carcinoid tumor * Metastatic or unresectable local-regional disease * Measurable disease * No osseous metastasis as the only site of disease * No history or clinical evidence of CNS disease (e.g., primary brain tumor or any brain metastasis) * Performance status - Zubrod 0-2 * Performance status - Karnofsky 70-100% * At least 12 weeks * See Immunologic * Absolute granulocyte count \> 1,500/mm\^3 * Platelet count \> 100,000/mm\^3 * Hemoglobin \> 8 g/dL * No bleeding diathesis or coagulopathy * No hemoglobinopathies (e.g., thalassemia) or any other cause of hemolytic anemia * Bilirubin \< 1.5 mg/dL * INR \< 1.5 (if receiving warfarin) * No evidence of decompensated liver disease (e.g., ascites, bleeding varices, or spontaneous encephalopathy) * Creatinine \< 1.5 mg/dL * No baseline proteinuria * Patients with proteinuria (≥ 2+ or ≥ 100 mg/dL on urinalysis) are allowed provided 24-hour urinary protein is \< 500 mg * No New York Heart Association grade II-IV congestive heart failure * No serious cardiac arrhythmia requiring medication * No clinically significant peripheral vascular disease * No history of stroke * None of the following within the past 6 months: * Uncontrolled hypertension * Transient ischemic attack * Cerebrovascular accident * Unstable angina * Myocardial infarction * No chronic pulmonary disease (e.g., chronic obstructive pulmonary disease) * No documented pulmonary hypertension * None of the following immunologically mediated diseases: * Inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis) * Rheumatoid arthritis * Idiopathic thrombocytopenia purpura * Systemic lupus erythematosus * Autoimmune hemolytic anemia * Scleroderma * Severe psoriasis * No serious concurrent infections * No active infection requiring parental antibiotics on day 0 * No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies * No known hypersensitivity to interferon alfa or to any excipient or vehicle included in its formulation or delivery system * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No significant traumatic injury within the past 4 weeks * No preexisting thyroid abnormality for which thyroid function can not be normalized by medication * No concurrent nonmalignant uncontrolled medical illness or one whose control may be jeopardized by the complications of this study therapy * No uncontrolled psychiatric disorder * No psychiatric disorders that would preclude study compliance * No other malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix * No serious nonhealing wound ulcer or bone fracture * No seizures not controlled with standard medical therapy * Prior immunotherapy allowed * No prior interferon * No concurrent immunotherapy * At least 4 weeks since prior chemotherapy, including radiosensitizers * No more than 1 prior chemotherapy regimen, including radiosensitizers * No concurrent chemotherapy * At least 4 weeks since prior radiotherapy * Prior radiotherapy must not have contained the single evaluable lesion of this study in a radiation field * No concurrent radiotherapy * At least 4 weeks since prior major surgery or open biopsy (1 week for minor surgery) and recovered * No concurrent or recent full-dose anticoagulants or thrombolytic agents (except as required to maintain patency of preexisting, permanent indwelling IV catheters) * No concurrent chronic daily aspirin (more than 325 mg/day) or nonsteroidal anti-inflammatory medications known to inhibit platelet function